Want to see JP:4539 full AI Analyst Report?

Nippon Chemiphar Co., Ltd. (4539) Price & Analysis

1 Followers

4539 Stock Chart & Stats

¥1585.00

-¥7.00(-0.46%)

At close: Jan 08 4:00 PM EST

¥1585.00

-¥7.00(-0.46%)

Day’s Range― - ―

52-Week Range¥1,502.00 - ¥1,857.00

Previous CloseN/A

Volume500.00

Average Volume (3M)2.70K

Market Cap

¥5.78B

Enterprise Value¥17.12K

Total Cash (Recent Filing)¥9.69B

Total Debt (Recent Filing)¥19.02B

Price to Earnings (P/E)―

Beta0.19

Next Earnings

Nov 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.19%

Share Statistics

EPS (TTM)109.50

Shares Outstanding4,261,420

10 Day Avg. Volume5,610

30 Day Avg. Volume2,700

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)0.33

Price to Sales (P/S)0.19

P/FCF Ratio-27.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryThe sharp 2026 top-line rebound indicates renewed demand or improved product performance, strengthening the company’s revenue base. Sustained sales growth would provide operating leverage and support investment in its prescription portfolio.

Recurring Prescription ModelDomestic prescription sales and generic medicines can create recurring demand through established healthcare channels. Multiple dosage forms, regulatory approvals, and reliable supply provide a durable platform for serving hospitals, clinics, and pharmacies.

Moderate LeverageA relatively stable asset base and moderate leverage give Nippon Chemiphar financial flexibility compared with a heavily indebted pharmaceutical peer. Lower debt in 2026 may reduce balance-sheet pressure and support continued operations.

Bears Say

Thin, Volatile ProfitabilityThe revenue rebound has not translated into consistently strong earnings. Losses in 2024 and thin profits afterward indicate limited margin resilience, leaving results vulnerable to pricing pressure, product mix changes, and cost inflation.

Weak Cash GenerationPersistent free-cash-flow deficits reduce the company’s ability to fund development, debt reduction, and shareholder returns internally. Volatile operating cash flow also weakens confidence that reported earnings consistently convert into usable cash.

Low Returns On CapitalLow and inconsistent returns suggest the company is generating limited earnings from its capital base. Unless profitability improves, this constrains reinvestment efficiency and may limit the long-term value of its pharmaceutical assets.

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?

Nippon Chemiphar Co., Ltd. lowest stock price was ¥1502.00 and its highest was ¥1857.00 in the past 12 months.

What is Nippon Chemiphar Co., Ltd.’s market cap?

Nippon Chemiphar Co., Ltd.’s market cap is ¥5.78B.

When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?

Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is Nov 04, 2026 which is in 60 days.

How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?

Nippon Chemiphar Co., Ltd. released its earnings results on Jul 31, 2026. The company reported -¥26.46 earnings per share for the quarter.

Is Nippon Chemiphar Co., Ltd. overvalued?

According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nippon Chemiphar Co., Ltd. pay dividends?

Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.19%. See more information on Nippon Chemiphar Co., Ltd. dividends here

What is Nippon Chemiphar Co., Ltd.’s EPS estimate?

Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nippon Chemiphar Co., Ltd. have?

Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.

What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?

Nippon Chemiphar Co., Ltd. reported an EPS of -¥26.46 in its last earnings report. Following the earnings report the stock price went up 2.532%.

Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4539

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.